Education
About Us
Working with TipRanks
Follow Us
Infant Bacterial Therapeutics (SE:IBT.B)
:IBT.B
IBT.B Stock Chart & Stats
kr63.00
kr1.30(3.51%)
At close: 4:00 PM EST
kr63.00
kr1.30(3.51%)
Day’s Range― - ―
52-Week Rangekr31.20 - kr84.30
Previous CloseN/A
Volume1.01K
Average Volume (3M)13.37K
Market Cap
kr759.79M
Enterprise Valuekr590.21M
Total Cash (Recent Filing)kr176.32M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.18
Next Earnings
May 06, 2026EPS Estimate
-1.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.43
Shares Outstanding13,018,137
10 Day Avg. Volume5,917
30 Day Avg. Volume13,366
Financial Highlights & Ratios
PEG Ratio-2.50
Price to Book (P/B)4.24
Price to Sales (P/S)180517.03
P/FCF Ratio-6.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Infant Bacterial Therapeutics AB News
IBT.B FAQ
What was Infant Bacterial Therapeutics’s price range in the past 12 months?
Infant Bacterial Therapeutics lowest stock price was kr31.20 and its highest was kr84.30 in the past 12 months.
What is Infant Bacterial Therapeutics’s market cap?
Infant Bacterial Therapeutics’s market cap is kr759.79M.
When is Infant Bacterial Therapeutics’s upcoming earnings report date?
Infant Bacterial Therapeutics’s upcoming earnings report date is May 06, 2026 which is in 79 days.
How were Infant Bacterial Therapeutics’s earnings last quarter?
Infant Bacterial Therapeutics released its earnings results on Feb 06, 2026. The company reported -kr1.43 earnings per share for the quarter, beating the consensus estimate of -kr12.759 by kr11.329.
Is Infant Bacterial Therapeutics overvalued?
According to Wall Street analysts Infant Bacterial Therapeutics’s price is currently Overvalued.
Does Infant Bacterial Therapeutics pay dividends?
Infant Bacterial Therapeutics does not currently pay dividends.
What is Infant Bacterial Therapeutics’s EPS estimate?
Infant Bacterial Therapeutics’s EPS estimate is -1.41.
How many shares outstanding does Infant Bacterial Therapeutics have?
Infant Bacterial Therapeutics has 13,018,137 shares outstanding.
What happened to Infant Bacterial Therapeutics’s price movement after its last earnings report?
Infant Bacterial Therapeutics reported an EPS of -kr1.43 in its last earnings report, beating expectations of -kr12.759. Following the earnings report the stock price went up 7.419%.
Which hedge fund is a major shareholder of Infant Bacterial Therapeutics?
Currently, no hedge funds are holding shares in SE:IBT.B
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Infant Bacterial Therapeutics
Infant Bacterial Therapeutics AB (IBT.B) is a Swedish biopharmaceutical company focused on developing and commercializing drugs to prevent or treat diseases affecting premature infants. The company operates primarily in the healthcare and biotechnology sectors, with a core emphasis on leveraging its expertise in bacterial therapy to address unmet medical needs in neonatology. Its leading product candidate, IBP-9414, targets the prevention of necrotizing enterocolitis (NEC) in preterm infants, aiming to provide innovative solutions to improve infant health outcomes.
Technical Analysis
Xbrane Biopharma AB
―
Ascelia Pharma AB
―
Guard Therapeutics International AB
―
Immunicum AB
―
Cantargia AB
―